Program
sepofarsen
Also written as “QR-110”.
Its studies are mostly in Blindness · Optic Atrophy, Hereditary, Leber, led by 2 companies.
Drug pageSepofarsen: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Laboratoires Theaits history only | 31 open or running | phase 3since Feb 3, 2025 | May 1, 2017 | Nov 2027phase 3 · NCT06891443 |
| ProQR Therapeutics | 21 open or running | phase 3since Feb 21, 2019 | Feb 21, 2019 | none ahead |
Also a collaborator on its studies: Sepul Bio.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of ProQR Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Feb 21, 2019First study: phase 3 study in Leber Congenital Amaurosis 10First studyNCT03913143 · 36 enrolled · United States, Belgium, Brazil and more
- Jun 9, 2019Named sepofarsenINNProposed as its International Nonproprietary Name in WHO's List 121 · before, QR-110
- Apr 13, 2021Phase 3 study in Leber Congenital Amaurosis 10NCT04855045 · 15 enrolled · Belgium, Brazil, Canada and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 ProQR Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04855045Leber Congenital Amaurosis 10 · Belgium, Brazil, Canada and more | 3 | UNKNOWN | Dec 2023 | 15 |
| NCT03913143Leber Congenital Amaurosis 10 · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Jan 31, 2022 | 36 |
How it is read
Names in the registry
- “sepofarsen”, 3 entries
- “QR-110”, 2 entries
Conditions, from the studies’ own filings
- Blindness, 4 studies
- Optic Atrophy, Hereditary, Leber, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.